Baxter launches swine flu vaccine

Celvapan is one of two vaccines now available for swine flu prophylaxis in high-risk patients.

Celvapan should be used in accordance with official guidance. The dose recommendations are based on safety and immunogenicity data available from the administration of a vaccine containing 7.5 microgram HA derived from A/Vietnam/1203/2004 (H5N1) in adults, including the elderly. Doses were given on days 0 and 21.

The decision to use Celvapan in each age group should take into account the extent of the clinical data available with the version containing H5N1 antigen and the disease characteristics of the current influenza pandemic.

View Celvapan drug record

Further information: Baxter


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Compare COVID-19 vaccines with new MIMS table

Compare COVID-19 vaccines with new MIMS table

Key characteristics of available COVID-19 vaccines...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...